Haemonetics Corporation
NYQ: HAELive Quote
📈 ZcoreAI Score
Our AI model analyzes Haemonetics Corporation's price action across multiple timeframes using regression channels and statistical scoring.
Get HAE Z-Score →About Haemonetics Corporation
Healthcare
Medical Devices
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
📊 Fundamental Analysis
Haemonetics Corporation demonstrates a healthy profit margin of 13.3%.
The company recently reported -2.7% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is 19.3%, which exceeds the Healthcare sector average, reflecting efficient capital allocation.
At a current price of $57.32, HAE currently sits at the 25th percentile of its 52-week range (Range: $47.32 - $87.32).
💰 Valuation Insight
HAE trades at a 36.8% discount (PE: 15.79), which may represent a value opportunity given the sector average of 25.00. Analysts expect earnings growth, as indicated by a lower forward PE.
🏥 Financial Health
⚠️
Profit Margin
Moderate
🔴
Debt/Equity
Elevated
🔴
Revenue Growth
Weak
⚠️
Return on Equity
Moderate
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$2.68B
Trailing P/E
15.79
Forward P/E
10.80
Beta (5Y)
0.36
52W High
$87.32
52W Low
$47.32
Avg Volume
876K
Day High
Day Low